JERUSALEM (Reuters) – Israel’s CytoReason, which uses AI to develop disease models, said on Wednesday it has raised $80 million in a private funding round.
Nvidia, Pfizer, Thermo Fisher and venture capital investor OurCrowd participated in the round, CytoReason said.
The company said it intends to expand the application of its models to additional indications and increase its proprietary molecular and clinical data.
It also plans to open an office in Cambridge, Massachusetts, later this year.
In 2022, Pfizer expanded its partnership with CytoReason with an investment of 20 million dollars that could reach 110 million dollars by 2027.
“The rapid expansion of new technologies, such as artificial
intelligence, has enormous potential to help transform what is possible in human health,” said Mikael Dolsten, chief scientific officer at Pfizer.
“Our collaboration with CytoReason leverages its cutting-edge immunological multi-omics platform to enhance Pfizer’s own R&D capabilities and generate invaluable insights into new drug development pathways for patients.”
CytoReason said six of the world’s top 10 pharmaceutical companies use its technology to make data-driven decisions in immunology, inflammation, immuno-oncology, metabolism and other therapies.
areas using a computational disease model AI platform.
(Reporting by Steven Scheer; Editing by Jason Neely)
